AKAnastasia Krepkaia

Anastasia Krepkaia

*This is an algorithmically generated author record based on publicly available information.

Anastasia Krepkaia has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cases of human infection with highly pathogenic strains of the avian influenza A virus: risks and vaccination strategies

    by Elena I. Burtseva, Anastasia S. Krepkaia, Anna V. Ignatieva, Anastasiya Serggevna Krepkaya, Крепкая Анастасия Сергеевна

    For several decades, avian influenza viruses have been considered a source of new variants with pandemic potential based on all known influenza pandemics to date. This review provides examples of human infections with various subtypes of avian influenza A viruses since 1997, when the first cases of human infection with highly pathogenic (H5N1) avian influenza viruses were reported in Hong Kong. In recent years, the World Health Organization has reported the largest number of human avian influenza virus infections in the Pacific region. An unusual outbreak of avian influenza A(H5N1) has been documented among cows and birds in the United States, with some farmers being infected as well. The article presents an analysis of infection risks, the properties and structure of strains, and their susceptibility to direct-acting antivirals. It also discusses vaccine development approaches, the strategy and tactics of vaccination within the WHO Pandemic Influenza Preparedness Framework and the Global Influenza Strategy.

  • Open Access

    The free-living ciliate Tetrahymena pyriformis inactivates engulfed influenza A(H1N1)pdm09 virus via two distinct types of endosomes

    by Valentina I. Pushkareva, Anastasia S. Krepkaia, Anna V. Ignatieva, Natalya V. Shevlyagina, Svetlana G. Andreevskaya, Elizaveta Fofanova, Elena V. Sysolyatina, Vladimir G. Zhukhovitsky, Elena I. Burtseva, Svetlana A. Ermolaeva

    Wild aquatic birds are a major reservoir of the influenza A virus in natural ecosystems, facilitating its entry into the aquatic microbial food web through their feces. Free-living protozoa and particularly bacterivorous ciliates are essential players of the microbial food web. This study investigates the interactions between the Influenza A(H1N1)pdm09 virus and the ciliated protozoan Tetrahymena pyriformis at the population and ultrastructural levels. Co-cultivation of Influenza A(H1N1)pdm09 and T. pyriformis resulted in a decline and eventual complete elimination of the viral population. The inactivation of the virus was not mediated by products excreted by T. pyriformis but required A(H1N1)pdm09 endocytosis. Viruses ingested by protozoa lost their virulence within 48 hours post infection (hpi) and, as determined by hemagglutination assays, were entirely inactivated within 72 hpi. When lysates infected with A(H1N1)pdm09 T. pyriformis were applied to MDCK cells 1.5 and 24 hpi the undamaged part of ingested virions caused a cytopathic effect. Confocal laser scanning microscopy (CLSM) and transmission electron microscopy (TEM) of infected T. pyriformis cells revealed large food vacuoles, including multiple undamaged and partly processed virus particles, at 1.5 and 24 hpi. Furthermore, TEM identified coated and half-coated small one-virus endosomes that predominated at 48 hpi. These results demonstrated that A(H1N1)pdm09 inactivation by T. pyriformis includes two types of endosomes that dominated at different periods of interpopulation interactions. The process of A(H1N1)pdm09 inactivation in protozoan cells occurs rapidly, but not instantaneously, that suggesting a dual role of protozoa in the fate of influenza A viruses in natural ecosystems, both as predators and as potential vectors.


  • Open Access

    Epidemic season 2023–2024: the palette of ARVI pathogens in some territories of the Russian Federation and WHO regions

    by Elena Burtseva, Nataliya Breslav, Evgenia Mukasheva, Kirill Krasnoslobodtsev, Elena Kirillova, Svetlana Trushakova, Irina Komarova, Elena Feodoritova, Anna Panova, Lidiya Kisteneva, et al.

    The purpose of this work was to determine the characteristics of the circulation of acute respiratory viral infection (ARVI) pathogens during the epidemic season of 2023–2024 in the WHO regions and Russian Federation. Materials and methods. The article uses virological, immunological, and statistical methods, analytical material from the WHO website, to assess the circulation of ARVI pathogens in the Russian Federation and WHO regions. Results and discussion. The detection rate of positive samples in clinical materials was as follows: influenza viruses – 7.7%, ARVI – 17.1% and SARS-CoV-2 – 6.5%. According to antigenic and molecular genetic properties, the population of the dominant subtype of the influenza A(H3N2) virus was heterogeneous and differed from the vaccine strain. The favorable sensitivity profile of epidemic strains to drugs with antineuraminidase activity (oseltamivir and zanamivir) and cap-dependent endonuclease inhibitor (baloxavir marboxil) was preserved. There was a tendency to increase the activity of respiratory pathogens such as HPIV, HAdV, HRsV, HRV, HCoV and HMPV. WHO experts have developed recommendations on the composition of influenza vaccines for the countries of the Northern and the Southern hemispheres with the replacement of the component of the influenza A(H3N2) virus: A/Darwin/9/2021 with A/Thailand/8/2022 and А/Croatia/13601RV/2023 accordingly. Cases of human infection with avian and swine influenza viruses continue to be registered. Conclusion. Against the background of a relatively low circulation of new SARS-CoV-2 variants in the 2023-2024 season, epidemic activity of influenza viruses was recorded in the countries of the Northern hemisphere at the traditional time. Globally, its onset was associated with the influenza A(H3N2) virus, followed by an increase in the activity of the influenza A(H1N1) pdm09 virus and influenza B. As in previous seasons, differences in the proportion of influenza viruses in WHO regions, including cities of the Russian Federation, were traced.


  • Open Access

    Properties of influenza viruses that caused epidemic increases in morbidity in Russia and countries of the world during 2022–2023. The effectiveness of vaccine prophylaxis

    by Elena I. Burtseva, Ludmila V. Kolobukhina, Anna D. Panova, Evgeniya A. Mukasheva, Kirill G. Krasnoslobodtsev, Elena S. Kirillova, Natalia V. Breslav, Svetlana V. Trushakova, Irina A. Komarova, Elena L. Feodoritova, et al.

    The purpose of this work was to determine the characteristics of the circulation of various viral respiratory pathogens during the epidemic season 2022–2023 against the background of the ongoing evolutionary variability of SARS-CoV-2. Materials and methods. The article uses methods used in «traditional» and «hospital» epidemiological surveillance of acute respiratory viral infections. Results and discussion. The period from October 2022 to September 2023 was characterized by early and high activity of influenza A(H1N1)pdm09 virus, which was replaced by influenza B virus. The antigenic and genetic properties of strains were closely related to influenza vaccines viruses recommended by WHO experts for the current season. The effectiveness of influenza vaccines was confirmed (75.0%). All of the studied influenza A(H1N1)pdm09, A(H3N2) and B epidemic strais retained sensitivity to drugs with antineuraminidase activity. The structure and share of other ARVI pathogens have changed somewhat compared to the previous season: There was a tendency to increase the activity of HAdV and HMPV; almost equivalent activity of HRsV, HRV, HCoV and HBoV; and a decrease in HPIV activity. At the same time, the frequency of other ARVI pathogens did not reach the indicators of the pre-pandemic COVID-19 period. The rationale for updating the composition of influenza vaccines for the countries of the Northern Hemisphere in the 2023–2024 season is given.


  • Open Access

    Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response

    by Elena P. Mazunina, Vladimir A. Gushchin, Denis A. Kleymenov, Andrey E. Sinyavin, Elena I. Burtseva, Maksim M. Shmarov, Evgenya A. Mukasheva, Evgeniia N. Bykonia, Sofia R. Kozlova, Elina A. Evgrafova, et al.

    : Seasonal influenza remains a serious global health problem, leading to high mortality rates among the elderly and individuals with comorbidities. It also imposes a substantial economic burden through increased absenteeism during periods of active pathogen circulation. Vaccination is generally accepted as the most effective strategy for influenza prevention. As both influenza A and B viruses circulate and cause seasonal epidemics, vaccines need to include multiple antigens derived from different viral subtypes. While current influenza vaccines are effective, they still have limitations, including narrow specificity for certain serological variants, which may result in a mismatch between vaccine antigens and circulating strains. Additionally, the rapid variability of the virus poses challenges in providing extended protection beyond a single season. Therefore, mRNA technology is particularly promising for influenza prevention, as it enables the rapid development of multivalent vaccines and allows for quick updates of their antigenic composition. mRNA vaccines have already proven successful in preventing COVID-19 by eliciting rapid cellular and humoral immune responses. In this study, we present the development of a trivalent mRNA vaccine candidates, evaluate its immunogenicity using the hemagglutination inhibition assay, and assess its efficacy in animals. We demonstrate the higher immunogenicity of the mRNA vaccine candidates compared to the inactivated split influenza vaccine and its enhanced ability to generate a cross-specific humoral immune response. These findings highlight the potential mRNA technology in overcoming current limitations of influenza vaccines and hold promise for ensuring greater efficacy in preventing seasonal influenza outbreaks.

  • Open Access

    Association of polymorphic variants of hemostatic system genes with the course of COVID-19

    by L I Nikolaeva, M D Stuchinskaya, A V Dedova, S G Nadezhda, I N Khlopova, I S Kruzhkova, L N Merkulova, L B Kisteneva, L V Kolobukhina, E A Mukasheva, et al.

    Introduction. COVID-19 is characterized by a varied clinical course. The aim of the work was to identify associations of SNPs of hemostatic system genes with COVID-19. Materials and methods. DNA was isolated from patients (n=117) and healthy participants (n=104). All infected patients were divided into 3 groups, depending on disease severity assessment, which was appreciated by NEWS2. Another group consisted of participants, who had asymptomatic infection in the past. Determination of SNPs of the genes FGB (-455 G/A), FII (20210 G/A), FV (1691 G/A), FVII (10976 G/A), FXIIIA1 (103 G/T), ITGA2 (807 C/T), ITGB3 (1565 T/C), SERPINE1 (-675 5G/4G) were performed by PCR using the “Genetics of Hemostasis” kit (“DNA-Technology”, Russia). Results. In analyzed SNPs, no significant differences were detected between the group of infected patients and healthy participants. But significant association was revealed in gene SERPINE1 (-675 5G/4G), when patient groups, differing in the disease severity, were analyzed relative to the group of participants with asymptomatic infection (p=0.0381; p=0 .0066; p=0.0009). It was found, that as COVID-19 severity scores increased, the proportion of 5G allele of gene SERPINE1 decreased, and the proportion of the 4G allele increased (p=0.005; p=0.009; p=0.0005). Similar processes were observed for genotypes 5G/5G and 4G/4G. Discussion. The gene SERPINE1 (-675 5G/4G) is associated with the severity of COVID-19. Conclusion. For the first time, it was discovered that 5G/5G genotype of gene SERPINE1 (-675 5G/4G) can be a marker of a milder course of COVID-19, and the 4G/4G genotype as a more severe one.


  • Open Access

    Epidemic season 2021–2022: Frequency of co-infection by respiratory viral pathogens

    by Elena I. Burtseva, Anna D. Panova, Ludmila V. Kolobukhina, Anna V. Ignatjeva, Elena S. Kirillova, Natalia V. Breslav, Svetlana V. Trushakova, Evgeniya A. Mukasheva, Elena L. Feodoritova, Kirill G. Krasnoslobodtsev, et al.

    BACKGROUND: This study was conducted to determine the characteristics of various viral respiratory pathogens spreading during the epidemic season 20212022 and the frequency of co-infection with SARS-CoV-2 and influenza. AIM: To assess the development of the influenza epidemic and frequency of cases of co-infection with respiratory pathogens in patients with acute respiratory viral infections between 2021 and 2022. MATERIALS AND METHODS: Traditional and hospital epidemiological surveillance methods for acute respiratory viral infections were used. RESULTS: The epidemic season of 20212022 was characterized by the early activity of the influenza A(H3N2) virus and the emergence and rapid spread of the omicron variant of SARS-CoV-2. The distribution of different respiratory pathogens during the epidemic season 20212022 was clearly traced: SARS-CoV-2 (18.8%) was predominant, followed by influenza viruses (10.6%) and pathogens of other acute respiratory viral infections (0.43.7%). With respect to influenza A (H3N2) and B viruses, the heterogeneity of their populations and drift variability in relation to vaccine strains were noted. DISCUSSION: The frequency of co-infection with various respiratory pathogens was low, i.e., it was no more than 0.1%according to traditional surveillance, and no more than 9.2% in the hospital surveillance. The rationale for updating the composition of influenza vaccines for the countries in the Northern Hemisphere for 20222023 season was identified. CONCLUSION: At present, early diagnosis of influenza is important given the availability of effective drugs with a direct mechanism of action for the prevention and treatment of this pathogen. Timely use of anti-influenza drugs will reduce the risks of a severe course, complications, and death, including co-infection with SARS-CoV-2.


  • Open Access

    Baloxavir marboxil as a new specific anti-influenza drug

    by Natalia V. Breslav, Anna V. Ignatjeva, Evgeniya A. Mukasheva, Anastasiya S. Krepkaia, Elena I. Burtseva, Крепкая Анастасия Сергеевна

    Baloxavir marboxil is the first antiviral drug with a unique single dose, registered in Russia in September 2020 under the trade name Xoflusa, for treating infection caused by influenza A and B viruses. This article presents an overview of studies on the anti-influenza activity of baloxavir marboxil by foreign colleagues. Data from scientific articles by different authors were analyzed and in vitro results and clinical data were considered, which can help in making recommendations for the use of the drug for the treatment and postexposure prophylaxis of influenza. Baloxavir marboxil acts as a selective low-molecular-weight inhibitor of an enzyme specific to the influenza virus in the viral RNA polymerase complex and is effective against strains resistant to oseltamivir. In the combined phenotypic analysis and analysis based on the sequence in the polymerase acidic (PA) protein, the frequency of viruses showing reduced susceptibility to the drug remains low. Numerous studies have demonstrated the safety profile and productivity of influenza treatment in various groups (without risk factors and high-risk patients). Baloxavir marboxil stops the replication of the influenza virus in the early stages, which terminates its release during the first day and significantly relieves the patients condition on the second day. Monitoring of the antiviral activity of the drug, especially in children aged 12 years and people with weakened immunity, should be closely monitored to develop clinical recommendations and prevent the formation of substitutions I38(T/F/M/S/L/V) in the PA of influenza A and B viruses that reduce their sensitivity to the drug.